The Technical Analyst
Select Language :
MorphoSys AG [MOR]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

MorphoSys AG Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

MorphoSys AG is listed at the  Exchange

-0.22% $18.14

America/New_York / 27 mar 2024 @ 16:00


FUNDAMENTALS
MarketCap: 2 729.77 mill
EPS: -1.500
P/E: -12.09
Earnings Date: Apr 29, 2024
SharesOutstanding: 150.48 mill
Avg Daily Volume: 2.14 mill
RATING 2024-03-27
S
Strong Buy
RATINGS
Rating CashFlow: Neutral
Return On Equity: Strong Buy
Return On Asset: Strong Buy
DE: Strong Buy
P/E: Strong Buy
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -12.09 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-2.06x
Company: PE -12.09 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 17.72 - 18.56

( +/- 2.33%)
ATR Model: 14 days

Forecast: 16:00 - $18.14

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $18.14
Forecast 2: 16:00 - $18.14
Forecast 3: 16:00 - $18.14
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $18.14 (-0.22% )
Volume 0.285 mill
Avg. Vol. 2.14 mill
% of Avg. Vol 13.32 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for MorphoSys AG

Last 12 Months

Last 12 months chart data with high, low, open and close for MorphoSys AG

RSI

Intraday RSI14 chart for MorphoSys AG

Last 10 Buy & Sell Signals For MOR

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35buy$17.18N/AActive
Profile picture for
            MorphoSys AG

MOR

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Last 10 Buy Signals

Date Signal @
SKLUSDMar 28 - 06:42$0.120
^FTMCMar 28 - 06:2219 808
^FTLCMar 28 - 06:224 382.80
P2PSUSDMar 28 - 06:33204.35
AUCTIONUSDMar 28 - 06:3524.70
FXSUSDMar 28 - 06:30$7.70
ZRXUSDMar 28 - 06:27$1.086
C98USDMar 28 - 06:270.399
WETHUSDMar 28 - 06:243 580.01
MSOLUSDMar 28 - 06:23219.13

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.